Patients

Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
Clinical News

Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. announced that it has submitted a New Drug Application (NDA) for Mitapivat to the U.S. Food and Drug Administration (FDA) for the treatment of adults with pyruvate…
TIF e-Academy: Reimagining Thalassaemia and Sickle Cell Disease Education
Νέα του TIF

TIF e-Academy: Reimagining Thalassaemia and Sickle Cell Disease Education

Read. Learn. Empower. The Thalassaemia International Federation´s internationally acclaimed Educational Programme is a fundamental component of TIF´s work and is specifically designed for and addressed to the ever-growing learning needs…
New Paper From Blood and Beyond Outlines How To Learn From The Impact Of The COVID-19 Crisis On Blood Use
Νέα

New Paper From Blood and Beyond Outlines How To Learn From The Impact Of The COVID-19 Crisis On Blood Use

The multi-stakeholder Blood and Beyond initiative recently published a policy briefing shedding light on how the COVID-19 pandemic affects blood use, blood transfusion services, and patients in whom transfusions are…
Ali Sattarpour: ”Thalassaemia did not stop me from living a normal life”
Νέα

Ali Sattarpour: ”Thalassaemia did not stop me from living a normal life”

In occasion of the International Thalassaemia Day 2021, Ali Sattarpour, 45, France, Fédération SOS GLOBI Vice President and TIF’s Thalassaemia Patient Advocacy Group (T-PAG) Member, recounts a life of struggles,…
TIF’s Statement on Accessibility of Gene Therapy for Thalassaemia
Press Releases

TIF’s Statement on Accessibility of Gene Therapy for Thalassaemia

The Thalassaemia International Federation (TIF) expresses its disappointment about the outcome of the reimbursement negotiation process concerning gene therapy (Zynteglo™) for transfusion-dependent thalassaemia patients, announced last week. The Federation’s distress…
Take Action For The International Thalassaemia Day 2021
Νέα

Take Action For The International Thalassaemia Day 2021

INTERNATIONAL THALASSAEMIA DAY 2021 – 8 MAY  ”Addressing Health Inequalities Across the Global Thalassaemia Community” Each year, individuals around the globe band together for one day of pure and empowering…
Oxbryta Increased Haemoglobin And Reduced Haemolysis in Adults and Adolescents With SCD
Clinical News

Oxbryta Increased Haemoglobin And Reduced Haemolysis in Adults and Adolescents With SCD

Global Blood Therapeutics, Inc. announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study of Oxbryta® (voxelotor) tablets in patients with sickle cell disease…
The International Thalassaemia Day 2021 Official Page is Now Live!
Νέα

The International Thalassaemia Day 2021 Official Page is Now Live!

INTERNATIONAL THALASSAEMIA DAY 2021 – 8 MAY  ”Addressing Health Inequalities Across the Global Thalassaemia Community” Visit the International Thalassaemia Day page, now LIVE on TIF website, to find out why…
Hemanext® Inc. Receives CE Mark Certification For Innovative Red Blood Cell (RBC) Processing & Storage System
Clinical News

Hemanext® Inc. Receives CE Mark Certification For Innovative Red Blood Cell (RBC) Processing & Storage System

Hemanext Inc. announced today it has received a CE Certificate of Conformity for the CE Mark for its Hemanext ONE Red Blood Cell (RBC) Processing and Storage System, allowing the…
Back to top button